Xencor (NASDAQ:XNCR) Trading 4.9% Higher – Should You Buy?

Shares of Xencor, Inc. (NASDAQ:XNCR) rose 4.9% during mid-day trading on Tuesday . The company traded as high as $9.39 and last traded at $9.38. Approximately 360,465 shares were traded during mid-day trading, a decline of 41% from the average daily volume of 615,783 shares. The stock had previously closed at $8.94.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Wells Fargo & Company decreased their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Xencor currently has an average rating of “Moderate Buy” and an average price target of $34.38.

Xencor Trading Up 6.9 %

The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $673.26 million, a PE ratio of -2.99 and a beta of 0.90. The business has a 50 day moving average price of $12.90 and a 200-day moving average price of $19.01.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Institutional Investors Weigh In On Xencor

Institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC raised its holdings in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,040 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Xencor during the 4th quarter valued at $34,000. GAMMA Investing LLC increased its position in Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV raised its holdings in shares of Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 813 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in shares of Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,337 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.